Disability outcomes and dose escalation with etanercept, adalimumab, and infliximab in rheumatoid arthritis patients: a US-based retrospective comparative effectiveness study

References

• Wolf F. The natural history of rheumatoid arthritis. J Rheumatol 1996;23(Suppl):13-22
   Google Scholar
• Moran MG. Psychiatric aspects of rheumatology. Psychiatr Clin N Am 1996;19:575-87
   PubMed Web of Science ®Google Scholar
• Lawrence RC, Helmick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998;41:778-99
   PubMed Web of Science ®Google Scholar
• Helmick CG, Felson DT, Lawrence RC, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum 2008;58:15-25
   PubMed Web of Science ®Google Scholar
• Birnbaum H, Pike C, Kaufman R, et al. Societal cost of rheumatoid arthritis patients in the US. Curr Med Res Opin 2010;26:77-90
   PubMed Web of Science ®Google Scholar
• Methotrexate [package insert]. Princeton, NJ: Sandoz, Inc., 2010
   Google Scholar
• Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 Recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59:762-84
   PubMed Web of Science ®Google Scholar
• Etanercept [package insert]. Thousand Oaks, CA, USA: Amgen Inc. and Pfizer Inc., 2010
   Google Scholar
• Humira [package insert]. North Chicago, IL,l USA: Abbott Laboratories, 2008
   Google Scholar
• Remicade [package insert]. Malvern, PA, USA: Centocor, Inc., 2007
   Google Scholar
• Agarwal SK, Maier AL, Chibnik LB, et al. Pattern of infliximab utilization in rheumatoid arthritis patients at an academic medical center. Arthritis Rheum 2005;53:872-8
   PubMed Web of Science ®Google Scholar
• Ollendorf DA, Massarotti E, Birbara C, et al. Frequency, predictors, and economic impact of upward dose adjustment of infliximab in managed care patients with rheumatoid arthritis. J Manag Care Pharm 2005;11:383-93
   PubMedGoogle Scholar
• Stern R, Wolfe F. Infliximab dose and clinical status: results of 2 studies in 1642 patients with rheumatoid arthritis. J Rheumatol 2004;31:1538-45
   PubMed Web of Science ®Google Scholar
• Etemad L, Yu EB, Wanke LA. Dose adjustment over time of etanercept and infliximab in patients with rheumatoid arthritis. Manag Care Interface 2005;18:21-7
   PubMedGoogle Scholar
• Gilbert TD Jr, Smith D, Ollendorf DA. Patterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: a retrospective cohort study. BMC Musculoskelet Disord 2004;5:36
   PubMed Web of Science ®Google Scholar
• Finckh A, Simard JF, Gabay C, et al. Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis. Ann Rheum Dis 2006;65:746-52
   PubMed Web of Science ®Google Scholar
• Harley CR, Frytak JR, Tandon N. Treatment compliance and dosage administration among rheumatoid arthritis patients receiving infliximab, etanercept, or methotrexate. Am J Manag Care 2003;9(Suppl):136-44
   Google Scholar
• Ollendorf DA, Klingman D, Hazard E, et al. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population. Clin Ther 2009;31:825-35
   PubMed Web of Science ®Google Scholar
• Wu E, Chen L, Birnbaum H, et al. Retrospective claims data analysis of dosage adjustment patterns of TNF antagonists among patients with rheumatoid arthritis. Curr Med Res Opin 2008;24:2229-40
   PubMed Web of Science ®Google Scholar
• Gu NY, Huang Xy, Fox KM, et al. Claims data analysis of dosing and cost of TNF antagonists. Am J Pharm Benefits 2010;2:351-9
   Google Scholar
• Huang X, Gu NY, Fox KM, et al. Comparison of methods for measuring dose escalation of the subcutaneous TNF antagonists for rheumatoid arthritis patients treated in routine clinical practice. Curr Med Res Opin 2010;26:1637-45
   PubMed Web of Science ®Google Scholar
• Harrison DJ, Huang X, Globe D. Dosing patterns and costs of tumor necrosis factor inhibitor use for rheumatoid arthritis. Am J Health-Syst Pharm 2010;67:1281-7
   PubMed Web of Science ®Google Scholar
• Suarez-Almazor M, Ortiz Z, Lopez-Olivo M, et al. Infliximab and etanercept in rheumatoid arthritis: timing, dose escalation, and switching. Technology Report no 86. Canadian Agency for Drugs and Technologies in Health (CADTH), 2007
   Google Scholar
• Edrees AF, Misra SN, Abdou NI. Anti-tumor necrosis factor (TNF) therapy in rheumatoid arthritis: correlation of TNF-alpha serum level with clinical response and benefit from changing dose or frequency of infliximab infusions. Clin Exper Rheumatology 2005;23:469-74
   PubMed Web of Science ®Google Scholar
• Johnsen AK, Schiff MH, Mease PJ, et al. Comparison of 2 doses of etanercept (50 vs 100 mg) in active rheumatoid arthritis: a randomized double blind study. J Rheumatology 2006;33:659-64
   PubMed Web of Science ®Google Scholar
• Ariza-Ariza R, Navarro-Sarabia F, Hernandez-Cruz B, et al. Dose escalation of the anti-TNFa agents in patients with rheumatoid arthritis. A systematic review. Rheumatol 2007;46:529-32
   PubMed Web of Science ®Google Scholar
• Durez P, Van den Bosch F, Corluy L, et al. A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective study. Rheumatology 2005;44:465-8
   PubMed Web of Science ®Google Scholar
• Van Vollenhoven RF, Brannemark S, Klareskog L. Dose escalation of infliximab in clinical practice: improvements seen may be explained by a regression-like effect. Ann Rheum Dis 2004;63:426-30
   PubMed Web of Science ®Google Scholar
• Pavelka K, Jarosová K, Suchý D, et al. Increasing the infliximab dose in rheumatoid arthritis patients: a randomised, double blind study failed to confirm its efficacy. Ann Rheum Dis. 2009;68:1285-9
   PubMed Web of Science ®Google Scholar
• Bartelds GM, Krieckaert CL, Nurmohamed MT, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011;305:1460-8
   PubMed Web of Science ®Google Scholar
• Pascual-Salcedo D, Plasencia C, Ramiro S, et al. Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Rheumatology (Oxford) 2011;50:1445-52
   PubMed Web of Science ®Google Scholar
• Moots RJ, Haraoui B, Matucci-Cerinic M, et al. Differences in biologic dose-escalation, non-biologic and steroid intensification among three anti-TNF agents: evidence from clinical practice. Clin Exp Rheumatol 2011;29:26-34
   PubMed Web of Science ®Google Scholar
• Blom M, Kievit W, Kuper HH, et al. Frequency and effectiveness of dose increase of adalimumab, etanercept, and infliximab in daily clinical practice. Arthritis Care Res (Hoboken). 2010;62:1335-41
   PubMed Web of Science ®Google Scholar
• ARAMIS: Arthritis, Rheumatism and Aging Medical Information Systems. Available at: http://aramis.stanford.edu [Last accessed 6 April 2011]
   Google Scholar
• Fries JF, McShane DJ. ARAMIS (The American Rheumatism Association Medical Information System): a prototypical national chronic disease data bank. West J Med 1986;145:798-804
   PubMedGoogle Scholar
• Bruce B, Fries JF. The Arthritis, Rheumatism and Aging Medical Information System (ARAMIS): still young at 30 years. Clin Exp Rheumatol 2005;23(5 Suppl 39):S163-7
   PubMed Web of Science ®Google Scholar
• Singh G. Arthritis. Rheumatism and aging medical information system post-marketing surveillance program. J Rheumatol 2001;28:1174-9
   PubMed Web of Science ®Google Scholar
• Fries JF, Spitz PW, Kraines RG, et al. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45
   PubMed Web of Science ®Google Scholar
• den Broeder AA, Creemers MCW, van Gestel AM, et al. Dose titration using the Disease Activity Score (DAS28) in rheumatoid arthritis patients treated with anti-TNF-a. Rheumatology 2002;41:638-42
   PubMed Web of Science ®Google Scholar
• Bruce B, Fries J. The Stanford health assessment questionnaire (HAQ): a review of its history, issues, progress, and documentation. J Rheumatol 2003;30:167-78
   PubMed Web of Science ®Google Scholar
• Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol 1982;9:789-93
   PubMed Web of Science ®Google Scholar
• Ramey DR, Raynauld JP, Fries JF. The health assessment questionnaire 1992: status and review. Arthritis Care Res 1992;5:119-29
   PubMedGoogle Scholar
• Sidiropoulos P, Bertsias G, Kritikos HD, et al. Infliximab treatment for rheumatoid arthritis, with dose titration based on the Disease Activity Score: dose adjustments are common but not always sufficient to assure sustained benefit. Ann Rheum Dis 2004;63:144-8
   PubMed Web of Science ®Google Scholar
• Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987;15:657-80
   PubMedGoogle Scholar
• Lachenbruch PA. Equivalence testing. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Available at: http://www.fda.gov/OHRMS/DOCKETS/ac/01/slides/3735s1_02_Lachenbruch/sld001.htm [Last accessed 6 April 2011]
   Google Scholar
• Wolfe F, Michaud K, Strand V. Expanding the definition of clinical differences: from minimally clinically important differences to really important differences. Analyses in 8931 patients with rheumatoid arthritis. J Rheumatol 2005;32:583-9
   PubMed Web of Science ®Google Scholar
• Strand V, Scott DL, Emery P, et al. Leflunomide Rheumatoid Arthritis Investigators Groups. Physical function and health related quality of life: analysis of 2-year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis. J Rheumatol 2005;32:590-601
   PubMed Web of Science ®Google Scholar
• Mease PJ, Revicki DA, Szechinski J, et al. Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab: results of the Dose-Ranging Assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) Trial. J Rheumatol 2008;35:20-30
   PubMed Web of Science ®Google Scholar
• Zhang W, Bansback N, Guh D, et al. Short-term influence of adalimumab on work productivity outcomes in patients with rheumatoid arthritis. J Rheumatol 2008;35:1729-36
   PubMed Web of Science ®Google Scholar
• Khanna D, Cyhaniuk A, Bedenbaugh A. Use of TNF inhibitors in the US: utilization patterns and dose escalation from a representative US rheumatoid arthritis population. Poster presented at EULAR, London, UK; May 25–28, 2011
   Google Scholar
• Ortendahl M, Holmes T, Schettler JD, et al. The methotrexate therapeutic response in rheumatoid arthritis. J Rheumatol 2002;29:2084-91
   PubMed Web of Science ®Google Scholar
• Pope JE, Khanna D, Norrie D, et al. The minimally important difference for the Health Assessment Questionnaire in rheumatoid arthritis clinical practice is smaller than in randomized trials. J Rheumatol 2009;36:254-9
   PubMed Web of Science ®Google Scholar
• Wolfe F, Michaud K. Towards an epidemiology of rheumatoid arthritis outcome with respect to treatment: randomized controlled trials overestimate treatment response and effectiveness. Rheumatology 2005;44(Suppl 4):iv18-iv22
   PubMedGoogle Scholar
• Michaud K, Messer J, Choi HK, et al. Direct costs and their predictors in patients with rheumatoid arthritis. Arthritis Rheum 2003;48:2750-62
   PubMed Web of Science ®Google Scholar
• Fautrel B, Woronoff-Lemsi M-C, Ethgen M, et al. Impact of medical practices on the costs of management of rheumatoid arthritis by anti-TNFa biological therapy in France. Joint Bone Spine 2005;72:550-6
   PubMed Web of Science ®Google Scholar
• Merkesdal S, Ruof J, Mittendorf T, et al. Cost-effectiveness of TNF-a-blocking agents in the treatment of rheumatoid arthritis. Expert Opin Pharmacotherapy 2004;5:1881-6
   PubMed Web of Science ®Google Scholar